	US 12,319,652 B2
	Salts and solid forms of (R)-1-(5-methoxy-1H-indol-1-yl)-N,N-dimethylpropan-2-amine
Matthew Duncton, San Bruno, CA (US); and Samuel Clark, New York, NY (US)
Assigned to Terran Biosciences Inc., Miami Beach, FL (US)
Filed by Terran Biosciences Inc., New York, NY (US)
Filed on Mar. 2, 2023, as Appl. No. 18/177,408.
Application 18/177,408 is a continuation of application No. 17/988,753, filed on Nov. 16, 2022, abandoned.
Claims priority of provisional application 63/319,735, filed on Mar. 14, 2022.
Claims priority of provisional application 63/316,924, filed on Mar. 4, 2022.
Claims priority of provisional application 63/310,977, filed on Feb. 16, 2022.
Claims priority of provisional application 63/280,084, filed on Nov. 16, 2021.
Claims priority of provisional application 63/280,085, filed on Nov. 16, 2021.
Prior Publication US 2024/0034718 A1, Feb. 1, 2024
Int. Cl. C07D 209/08 (2006.01)

CPC C07D 209/08 (2013.01) [C07B 2200/13 (2013.01)]

30 Claims

1. A (R)-1-(5-methoxy-1H-indol-1-yl)-N,N-dimethylpropan-2-amine (compound 1) monofumarate salt, wherein the compound 1 monofumarate salt is a crystalline polymorphic form characterized by XRPD signals at two signals or more, or three signals, selected from the group consisting of 14.0°2θ, 15.9°2θ, and 22.3°2θ (±0.2°2θ; ±0.1°2θ; or ±0.0°2θ; Cu Kα1 radiation).